Earlier this year (April 2025), Lilly reported positive Phase III results for orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for treating Type 2 diabetes and obesity
While members of these GPCR families were under active investigation as drug targets for the treatment of type 2 diabetes mellitus (T2DM), due to lack of efficacy, the number of drugs in the pipeline has been drastically reduced
However, studies have shown that it may be associated with weight loss in individuals with type 2 diabetes
For example: A 300 lb person on GLP-1s may lose 4560 lbs
Never stop prescribed medications without consulting your GP
But if several are present together, its worth reviewing your daily protein log and identifying where intake may be falling short